TruSight Oncology 500 is a next-generation sequencing (NGS) tumor profiling assay that analyzes hundreds of cancer-related biomarkers. It supports identification of all relevant DNA and RNA* variants implicated in various tumor types.
In addition, it accurately measures the key immunotherapy biomarkers: tumor mutation burden (TMB) and microsatellite instability (MSI).
Save Time, Money, and Samples through Test Consolidation
- Pan-cancer content aligned with key guidelines
- DNA + RNA* assay targeting 523 genes for assessment of small variants, TMB, MSI, splice variants, and fusions
- Identify relevant alterations while achieving highly accurate results